Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MORU’s Lao PDR targeted malaria elimination (TME) team recently installed 8 hand pumps to provide safe drinking water in 4 villages in Nong District, Savannakhet Province after villagers requested the pumps in return for participating in a TME project.

Children pumping up water and drinking it

Funded by the Bill and Melinda Gates Foundation, the TME project seeks to accelerate malaria elimination by providing mass drug administrations to communities with a relatively high P. falciparum prevalence that are covered by village health malaria workers and which have access to long lasting insecticide treated bed nets.

Gates funded TME project operates in four Greater Mekong Subregion countries: Myanmar, Cambodia, Lao PDR and Viet Nam. LOMWRU’s Dr Mayfong Mayxay is the principal investigator (PI) for the Lao PDR study, while Dr Koukeo Phommasone is the field site PI.

Savannakhet has the third highest malaria incidence of Laos’ 18 provinces. A survey conducted in 18 rural Savannakhet villages in 2015 using uPCR detected Plasmodium infections in 175 of 888 samples (20%). Most villages in Savannakhet are relatively accessible and malaria elimination is a high priority for the local government.

A pilot project to eliminate malaria was initiated in four villages in April 2016. The project showed that mass drug administration (MDA) in Savannakhet is feasible and well accepted, with more than 80% of the targeted villagers participating in three rounds of drug administrations.

The drug regimen consists of three monthly rounds (M0, M1 and M2) of three daily treatment doses of DHA/piperaquine (7 mg/kg dihydroartemisinin and 55 mg/kg piperaquine phosphate) combined with a single low dose primaquine (15mg or 0.25mg/kg). Frequency and timing of the MDA rounds relates to the modeled maximum effects on transmission reduction and the post-treatment prophylactic effect of piperaquine, which is around 30 days in sensitive strains.

All residents in the study villages are encouraged to take part in three rounds except for women in the first trimester of pregnancy and children under 6 months of age. A single low dose primaquine is sufficient to clear rapidly gametocytes which are not susceptible to schizontocidal drugs but does not clear hypnozoites and therefore does not prevent P. vivax relapses. During the MDAs, all drugs were administered under direct observation of study staff.

Similar stories

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

ASM Editor in conversation with Nick White

Malaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world’s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.

New Pandemic Sciences Centre at the University of Oxford

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.

Arjen Dondorp, Peter Horby and Rose McGready elected Academy of Medical Sciences Fellows

"Although it is hard to look beyond the pandemic right now," says President of the Academy of Medical Sciences Professor Dame Anne Johnson, "I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration."